420 related articles for article (PubMed ID: 24378099)
1. [Autologous cytokine-induced killer cells therapy on the quality of life of patients with breast cancer after adjuvant chemotherapy: a prospective study].
Liang XF; Ma DC; Ding ZY; Liu ZZ; Guo F; Liu L; Yu HY; Han YL; Xie XD
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):764-8. PubMed ID: 24378099
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
3. Clinical effects of immunotherapy of DC-CIK combined with chemotherapy in treating patients with metastatic breast cancer.
Mao Q; Li L; Zhang C; Sun Y; Liu S; Cui S
Pak J Pharm Sci; 2015 May; 28(3 Suppl):1055-8. PubMed ID: 26051718
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.
Wu C; Jiang J; Shi L; Xu N
Anticancer Res; 2008; 28(6B):3997-4002. PubMed ID: 19192663
[TBL] [Abstract][Full Text] [Related]
5. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
Peppercorn J; Herndon J; Kornblith AB; Peters W; Ahles T; Vredenburgh J; Schwartz G; Shpall E; Hurd DD; Holland J; Winer E
Cancer; 2005 Oct; 104(8):1580-9. PubMed ID: 16118805
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
Leinert E; Singer S; Janni W; Harbeck N; Weissenbacher T; Rack B; Augustin D; Wischnik A; Kiechle M; Ettl J; Fink V; Schwentner L; Eichler M
Clin Breast Cancer; 2017 Apr; 17(2):100-106. PubMed ID: 27884722
[TBL] [Abstract][Full Text] [Related]
7. Comparison of EQ-5D scores among anthracycline-containing regimens followed by taxane and taxane-only regimens for node-positive breast cancer patients after surgery: the N-SAS BC 02 trial.
Shiroiwa T; Fukuda T; Shimozuma K; Kuranami M; Suemasu K; Ohashi Y; Watanabe T
Value Health; 2011; 14(5):746-51. PubMed ID: 21839414
[TBL] [Abstract][Full Text] [Related]
8. Maintenance therapy with autologous cytokine-induced killer cells in patients with advanced epithelial ovarian cancer after first-line treatment.
Liu J; Li H; Cao S; Zhang X; Yu J; Qi J; An X; Yu W; Ren X; Hao X
J Immunother; 2014; 37(2):115-22. PubMed ID: 24509174
[TBL] [Abstract][Full Text] [Related]
9. Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study.
Zhang J; Zhu L; Du H; He X; Yin Y; Gu Y; Liu L; Lu K; Guo R; Liu P; Shu Y
Biomed Pharmacother; 2015 Mar; 70():248-52. PubMed ID: 25776508
[TBL] [Abstract][Full Text] [Related]
10. Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients.
Kool M; Fontein DB; Meershoek-Klein Kranenbarg E; Nortier JW; Rutgers EJ; Marang-van de Mheen PJ; van de Velde CJ
Breast; 2015 Jun; 24(3):224-9. PubMed ID: 25704982
[TBL] [Abstract][Full Text] [Related]
11. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies.
Niu Q; Wang W; Li Y; Qin S; Wang Y; Wan G; Guan J; Zhu W
Int Immunopharmacol; 2011 Apr; 11(4):449-56. PubMed ID: 21215350
[TBL] [Abstract][Full Text] [Related]
12. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study.
Fan HG; Houédé-Tchen N; Yi QL; Chemerynsky I; Downie FP; Sabate K; Tannock IF
J Clin Oncol; 2005 Nov; 23(31):8025-32. PubMed ID: 16258100
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23.
Land SR; Kopec JA; Yothers G; Anderson S; Day R; Tang G; Ganz PA; Fisher B; Wolmark N
Breast Cancer Res Treat; 2004 Jul; 86(2):153-64. PubMed ID: 15319567
[TBL] [Abstract][Full Text] [Related]
14. Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial.
Yang B; Lu XC; Yu RL; Chi XH; Liu Y; Wang Y; Dai HR; Zhu HL; Cai LL; Han WD
Hematol Oncol; 2012 Sep; 30(3):115-22. PubMed ID: 22972689
[TBL] [Abstract][Full Text] [Related]
15. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study.
Li R; Wang C; Liu L; Du C; Cao S; Yu J; Wang SE; Hao X; Ren X; Li H
Cancer Immunol Immunother; 2012 Nov; 61(11):2125-33. PubMed ID: 22581306
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial of an educational intervention for managing fatigue in women receiving adjuvant chemotherapy for early-stage breast cancer.
Yates P; Aranda S; Hargraves M; Mirolo B; Clavarino A; McLachlan S; Skerman H
J Clin Oncol; 2005 Sep; 23(25):6027-36. PubMed ID: 16135471
[TBL] [Abstract][Full Text] [Related]
17. High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment?
Macquart-Moulin G; Viens P; Palangié T; Bouscary ML; Delozier T; Roché H; Janvier M; Fabbro M; Moatti JP
J Clin Oncol; 2000 Feb; 18(4):754-64. PubMed ID: 10673516
[TBL] [Abstract][Full Text] [Related]
18. Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study.
Hiura Y; Takiguchi S; Yamamoto K; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Miyata H; Fujiwara Y; Mori M; Kangawa K; Doki Y
Cancer; 2012 Oct; 118(19):4785-94. PubMed ID: 22282373
[TBL] [Abstract][Full Text] [Related]
19. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer.
Pan K; Guan XX; Li YQ; Zhao JJ; Li JJ; Qiu HJ; Weng DS; Wang QJ; Liu Q; Huang LX; He J; Chen SP; Ke ML; Zeng YX; Xia JC
Clin Cancer Res; 2014 Jun; 20(11):3003-11. PubMed ID: 24668644
[TBL] [Abstract][Full Text] [Related]
20. How best to assess the quality of life in long-term survivors after surgery for NSCLC? Comparison between clinical predictors and questionnaire scores.
Sterzi S; Cesario A; Cusumano G; Corbo G; Lococo F; Biasotti B; Lapenna LM; Magrone G; Dall'armi V; Meacci E; Porziella V; Bonassi S; Margaritora S; Granone P
Clin Lung Cancer; 2013 Jan; 14(1):78-87. PubMed ID: 22607778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]